The ECAPS Act Explained: What Medicare Provider Status Means for Your Pharmacy

The Legislation Every Pharmacist Should Be Watching

For decades, pharmacists have operated under a frustrating contradiction. Patients trust them. Physicians refer to them. Public health campaigns rely on them. But Medicare does not recognize them as providers — which means pharmacists cannot bill directly for the clinical services they are already delivering.

The Equitable Community Access to Pharmacist Services Act, known as the ECAPS Act, is designed to change that. This bipartisan legislation would amend the Social Security Act to recognize pharmacists as providers under Medicare Part B, enabling direct reimbursement for a defined set of clinical services.

If it passes, ECAPS would represent the most significant expansion of pharmacist scope of practice at the federal level in years. And for independent pharmacy owners, it opens a revenue stream that PBMs cannot touch.

What the ECAPS Act Actually Does

The core of ECAPS is straightforward: it adds pharmacists to the list of practitioners eligible to bill Medicare Part B for certain services. Currently, that list includes physicians, nurse practitioners, physician assistants, and other licensed providers — but not pharmacists, despite the clinical training and licensure they hold.

Under ECAPS, pharmacists would be authorized to bill Medicare directly for test-to-treat clinical services. That means a patient walks into your pharmacy, you administer a rapid diagnostic test, interpret the results, and — where state law permits — prescribe and dispense the appropriate treatment. One visit, one provider, one location.

The specific services targeted by ECAPS include:

• Influenza — rapid testing, diagnosis, and treatment with antivirals like oseltamivir
• COVID-19 — point-of-care testing and treatment with authorized therapeutics
• Streptococcal pharyngitis — rapid strep testing and antibiotic prescribing where authorized
• RSV — testing and clinical assessment for respiratory syncytial virus

These are not experimental services. Pharmacists across the country are already performing many of them under state-level authorities and PREP Act extensions. What ECAPS does is create a federal payment mechanism so pharmacists actually get paid for the work.

Why This Matters for Independent Pharmacies

The financial implications are significant. Approximately $200 million in independent pharmacy opportunities are projected through clinical service programs this year alone. ECAPS would dramatically expand access to that revenue by creating a standardized, nationwide billing pathway through Medicare.

Consider the economics. A pharmacist-administered flu test-to-treat visit — including the rapid test, clinical assessment, and prescription — could generate $75 to $150 in direct reimbursement per encounter. That is revenue billed through the medical benefit, completely outside the PBM-controlled pharmacy benefit. No DIR fees. No spread pricing. No retroactive clawbacks.

For a pharmacy seeing even 10 test-to-treat patients per week, that translates to $39,000 to $78,000 in annual revenue from a single service category. Scale that across flu season surges, COVID waves, and year-round strep visits, and clinical services become a meaningful pillar of your business — not a side project.

This matters even more in the context of the PBM reimbursement crisis. Independent pharmacies are closing at a rate of roughly one per day, with more than half of owners losing money on the majority of Part D prescriptions. ECAPS offers a path to revenue that is earned directly from delivering patient care, with no middleman extracting margin along the way.

Where the Legislation Stands

ECAPS has been introduced with bipartisan support in both chambers of Congress. The bill has co-sponsors from both parties, which is significant — pharmacy provider status is not a partisan issue. Patient access, rural healthcare, and reducing unnecessary emergency department visits are priorities that cross the aisle.

Pharmacy organizations including the National Community Pharmacists Association, the American Pharmacists Association, and state pharmacy associations have made ECAPS a top legislative priority. The bill has been endorsed by a broad coalition of healthcare groups that recognize the role pharmacists play in frontline care delivery.

That said, the legislation still needs to move through committees, survive the budget scoring process, and reach a floor vote. Provider status expansions carry a cost estimate from the Congressional Budget Office, and finding budget offsets is always a hurdle. Previous versions of pharmacist provider status bills have stalled in committee, so passage is not guaranteed — but momentum is stronger than it has ever been.

How to Prepare Your Pharmacy Now

Whether ECAPS passes this session or in a subsequent one, the direction is clear: pharmacist-delivered clinical services are expanding, and reimbursement pathways are following. The pharmacies that will capture this revenue are the ones that build the infrastructure now.

Get Your Clinical Workflow Ready

If you are not already offering point-of-care testing and test-to-treat services, start building that capability. Invest in CLIA-waived testing equipment for flu, COVID, and strep. Train staff on clinical protocols. Establish standing orders or collaborative practice agreements with local physicians where your state requires them.

The pharmacies that have clinical workflows running before ECAPS passes will be able to bill from day one. The ones that wait will spend months building what they could have had in place.

Understand Your State Scope of Practice

ECAPS creates a federal billing mechanism, but the scope of services you can deliver still depends on state law. Some states already authorize pharmacist prescribing for test-to-treat conditions. Others require collaborative practice agreements or have more limited scope.

Know exactly what your state permits today. If your state pharmacy association is pushing scope-of-practice expansion legislation, get involved. Federal billing authority combined with broad state practice authority is the combination that maximizes revenue potential.

Build the Digital Infrastructure for Clinical Services

Clinical services require a different patient interaction model than traditional dispensing. Patients need to find your services, book appointments, complete intake forms, and receive follow-up communications. That means your pharmacy needs a digital presence purpose-built for clinical service delivery.

Think about what the patient experience looks like. A Medicare patient with flu symptoms searches for nearby test-to-treat pharmacies. They find your pharmacy online, see that you offer rapid flu testing and treatment, book a same-day appointment, and complete a brief health questionnaire before arriving. You administer the test, prescribe treatment, and the patient leaves with their medication in hand. Total time: 30 minutes. Total visits to other providers: zero.

That workflow requires online scheduling, digital intake forms, service listings, and the ability to communicate with patients before and after their visit. Pharmacies that can offer that seamless experience will capture significantly more clinical service volume than those relying on walk-in traffic alone.

Document Everything for Billing Readiness

Medicare billing requires documentation. Start building your clinical documentation habits now, even if you cannot yet bill Medicare for these services. Record every test-to-treat encounter with the same rigor you would use for a billable medical visit: patient demographics, chief complaint, test administered, result, clinical decision-making, treatment provided, and follow-up plan.

When the billing pathway opens, you will need compliant documentation from day one. Pharmacies that have been documenting clinical encounters all along will transition smoothly. Those that have been providing services informally will face a steep learning curve.

The Bigger Opportunity

ECAPS is not just about flu tests and strep swabs. It is a proof of concept. If pharmacists demonstrate that they can deliver test-to-treat services efficiently, with good outcomes, and at lower cost than emergency departments and urgent care clinics, the case for expanding provider status to additional services becomes overwhelming.

Medication therapy management, chronic disease monitoring, preventive health screenings, immunization counseling — all of these are services pharmacists are trained to provide and that Medicare could eventually reimburse directly. ECAPS is the door. What comes after it opens depends on how well pharmacists execute.

For independent pharmacy owners, the strategic imperative is clear. Clinical services represent a revenue category that grows your business, deepens patient relationships, and operates entirely outside the PBM reimbursement system that is squeezing traditional dispensing margins. Whether ECAPS passes this year or next, the pharmacies building clinical service capabilities and digital infrastructure today are the ones that will capture this opportunity when it arrives.

If you are thinking about how to offer clinical services online — appointment booking, telehealth consultations, patient intake, and service promotion — pharmacy-specific platforms can help you launch that digital presence without custom development or a six-figure budget. The important thing is to start building now, so your pharmacy is ready the moment the billing pathway opens.